If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 7 of 7
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Objective
Testing the role of DNA released from tumor cells into the blood in guiding the use of immunotherapy after surgical removal of the bladder for bladder cancer treatment.
Protocol No
ALLIANCE-A032103-MODERN
Categories
An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Objective
An Open-label, Multicenter Study of LY4050784 in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Protocol No
LOXO-J5M-OX-JOXA
Categories
Cancer,
Stomach,
Prostate,
Breast Cancers,
Other Skin,
Lip, Oral Cavity and Pharynx,
Larynx,
Ovary,
Head and Neck Cancers,
Thoracic Cancers,
Sarcoma,
Other Urologic,
Pancreas/Liver,
Cervix,
Gynecologic Cancers,
Esophagus,
Melanoma, Skin,
Bladder,
Gastrointestinal Cancers,
Prostate and Urologic Cancers,
Early Phase/Multiple Disease Site Cancers,
Skin Cancers
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Sol
Objective
A Phase 1A 1B Study of TEV-56278 in Patients with Selected Locally Advanced or Metastatic Solid Tumors
Protocol No
TEVA-TV56278-ONC-10203
Psycho-Spiritual Management for Patients with Advanced Cancer and their Family Caregivers
Objective
Psycho-Spiritual Management for Patients with Advanced Cancer and Family Caregivers
Protocol No
MDACC-2023-0450
A First-in-Human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients with Locally Advanced Un-Resectable and/or Metastatic Solid Tumors and Multiple Myeloma
Objective
Safety, PK and efficacy of QXL138AM in patients with solid tumors and multiple myeloma
Protocol No
NAMMI-QXL138AM-001
A Phase I/IIa First-in-Human Study of (212Pb)VMT-Alpha-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Objective
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
Protocol No
VMT-ALPHA-NET-T101
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors
Objective
A Phase 1 study of BG-75098 alone and in combination with BGB-43395 and/or Fulvestrant in Patients with Advanced Solid Tumors.
Protocol No
BEONE-BG-75098-101
Categories
Cancer,
Early Phase/Multiple Disease Site Cancers,
Other Respiratory,
Other Skin,
Pancreas/Liver,
Prostate,
Other Gynecologic,
Colorectal,
Skin Cancers,
Gynecologic Cancers,
Bladder,
Lung,
Other Gastrointestinal,
Esophagus,
Breast Cancers,
Esophagus,
Gastrointestinal Cancers,
Prostate and Urologic Cancers,
Sarcoma,
Lip, Oral Cavity and Pharynx,
Thoracic Cancers,
Head and Neck Cancers